General Information of the Ferroptosis Regulator (ID: REG10501)
Regulator Name Eukaryotic translation initiation factor 4E (EIF4E)
Synonyms
eIF-4F 25 kDa subunit; mRNA cap-binding protein
    Click to Show/Hide
Gene Name EIF4E
Gene ID 1977
Regulator Type Protein coding
Uniprot ID P06730
Sequence
MATVEPETTPTPNPPTTEEEKTESNQEVANPEHYIKHPLQNRWALWFFKNDKSKTWQANL
RLISKFDTVEDFWALYNHIQLSSNLMPGCDYSLFKDGIEPMWEDEKNKRGGRWLITLNKQ
QRRSDLDRFWLETLLCLIGESFDDYSDDVCGAVVNVRAKGDKIAIWTTECENREAVTHIG
RVYKERLGLPPKIVIGYQSHADTATKSGSTTKNRFVV

    Click to Show/Hide
Family Eukaryotic initiation factor 4E family
Function
Component of the protein complex eIF4F, which is involved in the recognition of the mRNA cap, ATP-dependent unwinding of 5'-terminal secondary structure and recruitment of mRNA to the ribosome (By similarity). This protein recognizes and binds the 7-methylguanosine- containing mRNA cap during an early step in the initiation of protein synthesis and facilitates ribosome binding by inducing the unwinding of the mRNAs secondary structures. Together with EIF4G1, antagonizes the scanning promoted by EIF1-EIF4G1 and is required for TISU translation, a process where the TISU element recognition makes scanning unnecessary. In addition to its role in translation initiation, also acts as a regulator of translation and stability in the cytoplasm. Component of the CYFIP1-EIF4E-FMR1 complex which binds to the mRNA cap and mediates translational repression: in the complex, EIF4E mediates the binding to the mRNA cap (By similarity). Component of a multiprotein complex that sequesters and represses translation of proneurogenic factors during neurogenesis (By similarity). In P-bodies, component of a complex that mediates the storage of translationally inactive mRNAs in the cytoplasm and prevents their degradation. May play an important role in spermatogenesis through translational regulation of stage-specific mRNAs during germ cell development (By similarity).

    Click to Show/Hide
HGNC ID
HGNC:3287
KEGG ID hsa:1977
Full List of the Ferroptosis Target of This Regulator and Corresponding Disease/Drug Response(s)
EIF4E can regulate the following target(s), and cause disease/drug response(s). You can browse detail information of target(s) or disease/drug response(s).
Browse Target
Browse Disease
Browse Drug
Unspecific Target [Unspecific Target]
In total 1 item(s) under this target
Experiment 1 Reporting the Ferroptosis Target of This Regulator [1]
Responsed Disease Hereditary Leiomyomatosis ICD-11: 2C90
Responsed Drug Everolimus Investigative
Pathway Response Ferroptosis hsa04216
Glutathione metabolism hsa00480
mTOR signaling pathway hsa04150
Cell Process Cell ferroptosis
In Vitro Model
ACHN cells Papillary renal cell carcinoma Homo sapiens CVCL_1067
Caki-1 cells Clear cell renal cell carcinoma Homo sapiens CVCL_0234
HEK293 cells Normal Homo sapiens CVCL_0045
Response regulation Everolimus and RSL3/Erastin could synergistically inhibit the viability and induce ferroptosis in Renal cell carcinoma cells. Mechanistically, the inhibition of the mTOR-4EBP1 axis was found to be essential for the synergistic effects of Everolimus and RSL3/Erastin. Everolimus in combination with RSL3/Erastin is a promising therapeutic option for RCC treatment.
Hereditary Leiomyomatosis [ICD-11: 2C90]
In total 1 item(s) under this disease
Experiment 1 Reporting the Ferroptosis-centered Disease Response [1]
Target Regulator Eukaryotic translation initiation factor 4E (EIF4E) Protein coding
Responsed Drug Everolimus Investigative
Pathway Response Ferroptosis hsa04216
Glutathione metabolism hsa00480
mTOR signaling pathway hsa04150
Cell Process Cell ferroptosis
In Vitro Model
ACHN cells Papillary renal cell carcinoma Homo sapiens CVCL_1067
Caki-1 cells Clear cell renal cell carcinoma Homo sapiens CVCL_0234
HEK293 cells Normal Homo sapiens CVCL_0045
Response regulation Everolimus and RSL3/Erastin could synergistically inhibit the viability and induce ferroptosis in Renal cell carcinoma cells. Mechanistically, the inhibition of the mTOR-4EBP1 axis was found to be essential for the synergistic effects of Everolimus and RSL3/Erastin. Everolimus in combination with RSL3/Erastin is a promising therapeutic option for RCC treatment.
Everolimus [Investigative]
In total 1 item(s) under this drug
Experiment 1 Reporting the Ferroptosis-centered Drug Response [1]
Drug for Ferroptosis Inducer
Response Target Unspecific Target
Responsed Disease Hereditary Leiomyomatosis ICD-11: 2C90
Pathway Response Ferroptosis hsa04216
Glutathione metabolism hsa00480
mTOR signaling pathway hsa04150
Cell Process Cell ferroptosis
In Vitro Model
ACHN cells Papillary renal cell carcinoma Homo sapiens CVCL_1067
Caki-1 cells Clear cell renal cell carcinoma Homo sapiens CVCL_0234
HEK293 cells Normal Homo sapiens CVCL_0045
Response regulation Everolimus and RSL3/Erastin could synergistically inhibit the viability and induce ferroptosis in Renal cell carcinoma cells. Mechanistically, the inhibition of the mTOR-4EBP1 axis was found to be essential for the synergistic effects of Everolimus and RSL3/Erastin. Everolimus in combination with RSL3/Erastin is a promising therapeutic option for RCC treatment.
References
Ref 1 Everolimus accelerates Erastin and RSL3-induced ferroptosis in renal cell carcinoma. Gene. 2022 Jan 30;809:145992. doi: 10.1016/j.gene.2021.145992. Epub 2021 Oct 11.